NEW YORK (GenomeWeb) – By combining whole-genome sequencing and artificial intelligence-based analysis, researchers have reported that they were able to quickly identify clinically actionable mutations within a brain tumor sample.
Researchers from the New York Genome Center, Rockefeller University, and IBM analyzed a glioblastoma sample through panel testing as well as whole-genome sequencing. That sequencing data was then analyzed by a team of bioinformaticians and oncologists at the center as well as by IBM's Watson for Genomics.